Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
After finishing at $160.82 in the prior trading day, GeneDx Holdings Corp (NASDAQ: WGS) closed at $158.57, down -1.40%. In other words, the price has decreased by -$1.40 from its previous closing price. On the day, 0.53 million shares were traded. WGS stock price reached its highest trading level at $165.62 during the session, while it also had its lowest trading level at $156.88.
Ratios:
Our goal is to gain a better understanding of WGS by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 29.56 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 296.28. For the most recent quarter (mrq), Quick Ratio is recorded 2.59 and its Current Ratio is at 2.71. In the meantime, Its Debt-to-Equity ratio is 0.39 whereas as Long-Term Debt/Eq ratio is at 0.37.
Upgrades & Downgrades
In the most recent recommendation for this company, Canaccord Genuity on October 20, 2025, initiated with a Buy rating and assigned the stock a target price of $155.
On July 09, 2025, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $110.
On May 15, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $88.Guggenheim initiated its Buy rating on May 15, 2025, with a $88 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 01 ’25 when Feeley Kevin sold 377 shares for $162.54 per share. The transaction valued at 61,276 led to the insider holds 4,193 shares of the business.
RUCH JOSHUA sold 38,000 shares of WGS for $6,093,967 on Nov 24 ’25. The Director now owns 11,941 shares after completing the transaction at $160.37 per share. On Nov 24 ’25, another insider, RUCH JOSHUA, who serves as the Director of the company, bought 38,000 shares for $160.37 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, WGS now has a Market Capitalization of 4583400960 and an Enterprise Value of 4541483008. As of this moment, GeneDx’s Price-to-Earnings (P/E) ratio for their current fiscal year is 2629.69, and their Forward P/E ratio for the next fiscal year is 361.59. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.14. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.40 while its Price-to-Book (P/B) ratio in mrq is 15.67. Its current Enterprise Value per Revenue stands at 11.292 whereas that against EBITDA is 131.018.
Stock Price History:
The Beta on a monthly basis for WGS is 2.05, which has changed by 1.2407691 over the last 52 weeks, in comparison to a change of 0.13042927 over the same period for the S&P500. Over the past 52 weeks, WGS has reached a high of $170.87, while it has fallen to a 52-week low of $55.17. The 50-Day Moving Average of the stock is 15.92%, while the 200-Day Moving Average is calculated to be 51.08%.
Shares Statistics:
The stock has traded on average 520.12K shares per day over the past 3-months and 402800 shares per day over the last 10 days, according to various share statistics. A total of 28.89M shares are outstanding, with a floating share count of 25.37M. Insiders hold about 12.23% of the company’s shares, while institutions hold 103.73% stake in the company. Shares short for WGS as of 1764288000 were 3594043 with a Short Ratio of 6.91, compared to 1761868800 on 3504577. Therefore, it implies a Short% of Shares Outstanding of 3594043 and a Short% of Float of 24.77.
Earnings Estimates
The stock of GeneDx Holdings Corp (WGS) is currently being evaluated by 7.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is $0.0, with high estimates of $0.07 and low estimates of -$0.12.
Analysts are recommending an EPS of between $1.47 and $1.29 for the fiscal current year, implying an average EPS of $1.38. EPS for the following year is $0.5, with 7.0 analysts recommending between $0.95 and $0.09.
Revenue Estimates
9 analysts predict $120.37M in revenue for. The current quarter. It ranges from a high estimate of $122.1M to a low estimate of $119.2M. As of. The current estimate, GeneDx Holdings Corp’s year-ago sales were $95.64MFor the next quarter, 9 analysts are estimating revenue of $116.81M. There is a high estimate of $119.8M for the next quarter, whereas the lowest estimate is $108.99M.
A total of 9 analysts have provided revenue estimates for WGS’s current fiscal year. The highest revenue estimate was $428.7M, while the lowest revenue estimate was $425.7M, resulting in an average revenue estimate of $426.93M. In the same quarter a year ago, actual revenue was $305.45MBased on 9 analysts’ estimates, the company’s revenue will be $527.38M in the next fiscal year. The high estimate is $545.6M and the low estimate is $506.6M.
